 |
市场调查报告书
商品编码
1434724
AlphaGlucosidase抑制剂市场：按药物类别、分销管道、最终用户划分 - 全球预测 2024-2030Alpha Glucosidase Inhibitors Market by Drug class (Acarbose (Precose), Miglitol (Glyset), Voglibose), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030 |
||||||
价格
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年α-Glucosidase抑制剂市场规模为61,676万美元，2024年达70376万美元，预计2030年将达159,149万美元，复合年增长率为14.50%。
α-Glucosidase抑制剂的全球市场
| 主要市场统计 | |
|---|---|
| 基准年[2023] | 61676万美元 |
| 预测年份 [2024] | 70376万美元 |
| 预测年份 [2030] | 15.9149亿美元 |
| 复合年增长率（%） | 14.50% |
FPNV定位矩阵
FPNV定位矩阵对于评估α-Glucosidase抑制剂市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。
市场占有率分析
市场占有率分析是一种综合工具，可以对阿尔法Glucosidase抑制剂市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。
该报告对以下几个方面提供了宝贵的见解：
1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。
2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。
3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。
本报告解决了以下关键问题：
1-α葡萄Glucosidase抑制剂市场的市场规模和预测是多少？
在 2-αGlucosidase抑制剂市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？
3-αGlucosidase抑制剂市场的技术趋势和法律规范是什么？
4-αGlucosidase抑制剂市场主要厂商的市场占有率是多少？
进入5-α葡萄Glucosidase抑制剂市场的合适型态和策略手段是什么？
目录
第一章 前言
第二章调查方法
第三章执行摘要
第四章市场概况
第五章市场洞察
- 市场动态
- 促进因素
- 2 型糖尿病的盛行率和改善护理的需要
- 鼓励糖尿病管理的政府措施和政策
- 与α-Glucosidase抑制剂的联合治疗越来越受到关注
- 抑制因素
- API核准和给药方案的困难
- 机会
- 持续研发活动以发现新的α-Glucosidase抑制剂
- 提高α-Glucosidase抑制剂疗效的个人化医疗方法
- 任务
- 对胃肠道副作用和药物交互作用的担忧
- 促进因素
- 市场区隔分析
- 市场趋势分析
- 高通膨的累积效应
- 波特五力分析
- 价值炼和关键路径分析
- 法律规范
第六章 αGlucosidase酶抑制剂市场：依药物类别
- Acarbose（预科）
- 米格列醇（Griset）
- 伏格里波糖
第七章αGlucosidase酶抑制剂市场：按分销管道
- 医院药房
- 网路药房
- 零售药房
第 8 章 αGlucosidase酶抑制剂市场：依最终用户分类
- 家庭保健
- 医院和诊所
- 糖尿病专科中心
第九章北美和南美αGlucosidase抑制剂市场
- 阿根廷
- 巴西
- 加拿大
- 墨西哥
- 美国
第十章亚太地区αGlucosidase酶抑制剂市场
- 澳洲
- 中国
- 印度
- 印尼
- 日本
- 马来西亚
- 菲律宾
- 新加坡
- 韩国
- 台湾
- 泰国
- 越南
第11章α-欧洲、中东和非洲的Glucosidase抑制剂市场
- 丹麦
- 埃及
- 芬兰
- 法国
- 德国
- 以色列
- 义大利
- 荷兰
- 奈及利亚
- 挪威
- 波兰
- 卡达
- 俄罗斯
- 沙乌地阿拉伯
- 南非
- 西班牙
- 瑞典
- 瑞士
- 土耳其
- 阿拉伯聯合大公国
- 英国
第十二章竞争形势
- FPNV定位矩阵
- 市场占有率分析：主要企业
- 主要企业竞争情境分析
第13章竞争产品组合
- 主要公司简介
- Alkem Laboratories Ltd.
- Avecia Healthcare
- Bal Pharma Ltd.
- Bayer AG
- Biocon
- BioVision Inc. by Abcam US Group Holdings Inc.
- Cipla Ltd.
- Elder Pharmaceuticals Ltd.
- Empros Pharma AB
- Glenmark Pharmaceuticals Ltd.
- Lunan Pharmaceuticals Group
- Manus Aktteva Biopharma LLP
- Merck KGaA
- Micro Labs Ltd.
- Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd.
- Novo Nordisk A/S
- Samex Overseas
- Sanofi SA
- Shenzhen Haorui Pharmatech Co., Ltd.
- Straight Healthcare
- Strides Arcolab Limited
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Torrent Pharmaceuticals Ltd.
- Wockhardt Ltd.
- 主要产品系列
第十四章附录
- 讨论指南
- 关于许可证和定价
Product Code: MRR-456C7E866938
[187 Pages Report] The Alpha Glucosidase Inhibitors Market size was estimated at USD 616.76 million in 2023 and expected to reach USD 703.76 million in 2024, at a CAGR 14.50% to reach USD 1,591.49 million by 2030.
Global Alpha Glucosidase Inhibitors Market
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 616.76 million |
| Estimated Year [2024] | USD 703.76 million |
| Forecast Year [2030] | USD 1,591.49 million |
| CAGR (%) | 14.50% |
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Alpha Glucosidase Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha Glucosidase Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Alpha Glucosidase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Avecia Healthcare, Bal Pharma Ltd., Bayer AG, Biocon, BioVision Inc. by Abcam US Group Holdings Inc., Cipla Ltd., Elder Pharmaceuticals Ltd., Empros Pharma AB, Glenmark Pharmaceuticals Ltd., Lunan Pharmaceuticals Group, Manus Aktteva Biopharma LLP, Merck KGaA, Micro Labs Ltd., Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd., Novo Nordisk A/S, Samex Overseas, Sanofi S.A., Shenzhen Haorui Pharmatech Co., Ltd., Straight Healthcare, Strides Arcolab Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Torrent Pharmaceuticals Ltd., and Wockhardt Ltd..
Market Segmentation & Coverage
This research report categorizes the Alpha Glucosidase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Drug class
- Acarbose (Precose)
- Miglitol (Glyset)
- Voglibose
- Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- End-Users
- Home Healthcare
- Hospitals & Clinics
- Specialty Diabetes Centers
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Alpha Glucosidase Inhibitors Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha Glucosidase Inhibitors Market?
3. What are the technology trends and regulatory frameworks in the Alpha Glucosidase Inhibitors Market?
4. What is the market share of the leading vendors in the Alpha Glucosidase Inhibitors Market?
5. Which modes and strategic moves are suitable for entering the Alpha Glucosidase Inhibitors Market?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
- 4.1. Introduction
- 4.2. Alpha Glucosidase Inhibitors Market, by Region
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Prevalence of type 2 diabetes and need for improved care
- 5.1.1.2. Government initiatives and policies encouraging diabetes management
- 5.1.1.3. Increasing focus on combination therapies with alpha-glucosidase inhibitors
- 5.1.2. Restraints
- 5.1.2.1. Difficulties of API approval and dosing regimen
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing R&D activities for new alpha-glucosidase inhibitor discovery
- 5.1.3.2. Personalized medicine approaches for improved alpha-glucosidase inhibitor efficacy
- 5.1.4. Challenges
- 5.1.4.1. Concerns associated with gastrointestinal side effects and drug interactions
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
6. Alpha Glucosidase Inhibitors Market, by Drug class
- 6.1. Introduction
- 6.2. Acarbose (Precose)
- 6.3. Miglitol (Glyset)
- 6.4. Voglibose
7. Alpha Glucosidase Inhibitors Market, by Distribution Channel
- 7.1. Introduction
- 7.2. Hospital Pharmacies
- 7.3. Online Pharmacies
- 7.4. Retail Pharmacies
8. Alpha Glucosidase Inhibitors Market, by End-Users
- 8.1. Introduction
- 8.2. Home Healthcare
- 8.3. Hospitals & Clinics
- 8.4. Specialty Diabetes Centers
9. Americas Alpha Glucosidase Inhibitors Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
10. Asia-Pacific Alpha Glucosidase Inhibitors Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
11. Europe, Middle East & Africa Alpha Glucosidase Inhibitors Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Alkem Laboratories Ltd.
- 13.1.2. Avecia Healthcare
- 13.1.3. Bal Pharma Ltd.
- 13.1.4. Bayer AG
- 13.1.5. Biocon
- 13.1.6. BioVision Inc. by Abcam US Group Holdings Inc.
- 13.1.7. Cipla Ltd.
- 13.1.8. Elder Pharmaceuticals Ltd.
- 13.1.9. Empros Pharma AB
- 13.1.10. Glenmark Pharmaceuticals Ltd.
- 13.1.11. Lunan Pharmaceuticals Group
- 13.1.12. Manus Aktteva Biopharma LLP
- 13.1.13. Merck KGaA
- 13.1.14. Micro Labs Ltd.
- 13.1.15. Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd.
- 13.1.16. Novo Nordisk A/S
- 13.1.17. Samex Overseas
- 13.1.18. Sanofi S.A.
- 13.1.19. Shenzhen Haorui Pharmatech Co., Ltd.
- 13.1.20. Straight Healthcare
- 13.1.21. Strides Arcolab Limited
- 13.1.22. Sun Pharmaceutical Industries Ltd.
- 13.1.23. Takeda Pharmaceutical Co. Ltd.
- 13.1.24. Torrent Pharmaceuticals Ltd.
- 13.1.25. Wockhardt Ltd.
- 13.2. Key Product Portfolio
14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
LIST OF FIGURES
- FIGURE 1. ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH PROCESS
- FIGURE 2. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ALPHA GLUCOSIDASE INHIBITORS MARKET DYNAMICS
- FIGURE 7. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 8. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 10. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
- FIGURE 12. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
LIST OF TABLES
- TABLE 1. ALPHA GLUCOSIDASE INHIBITORS MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 6. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ACARBOSE (PRECOSE), BY REGION, 2018-2030 (USD MILLION)
- TABLE 7. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MIGLITOL (GLYSET), BY REGION, 2018-2030 (USD MILLION)
- TABLE 8. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY VOGLIBOSE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 10. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 14. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SPECIALTY DIABETES CENTERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 18. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 19. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 20. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 21. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 22. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 23. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 24. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 25. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 26. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 27. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 28. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 29. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 30. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 31. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 32. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 33. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 34. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 35. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 36. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 37. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 38. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 39. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 40. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 41. AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 42. AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 43. AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 44. CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 45. CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 46. CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 47. INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 48. INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 49. INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 50. INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 51. INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 52. INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 53. JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 54. JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 55. JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 56. MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 57. MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 58. MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 59. PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 60. PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 61. PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 62. SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 63. SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 64. SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 65. SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 66. SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 67. SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 68. TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 69. TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 70. TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 71. THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 72. THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 73. THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 74. VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 75. VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 76. VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 77. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 78. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 79. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 80. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 81. DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 82. DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 83. DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 84. EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 85. EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 86. EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 87. FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 88. FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 89. FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 90. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 91. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 92. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 93. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 94. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 95. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 96. ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 97. ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 98. ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 99. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 100. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 101. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 102. NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 103. NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 104. NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 105. NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 106. NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 107. NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 108. NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 109. NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 110. NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 111. POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 112. POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 113. POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 114. QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 115. QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 116. QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 117. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 118. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 119. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 120. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 121. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 122. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 123. SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 124. SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 125. SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 126. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 127. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 128. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 129. SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 130. SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 131. SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 132. SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 133. SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 134. SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 135. TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 136. TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 137. TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 138. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 139. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 140. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 141. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 142. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 143. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
- TABLE 144. ALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
- TABLE 145. ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 146. ALPHA GLUCOSIDASE INHIBITORS MARKET LICENSE & PRICING
